3D Medicines Sets 31 Aug 2026 Board Meeting to Review H1 2026 Results and Potential Interim Dividend

Bulletin Express

Aug 17

3D Medicines Inc. has scheduled a board meeting for Monday, 31 August 2026. The agenda includes:

1. Approval of the unaudited interim results for the six months ended 30 June 2026. 2. Consideration of an interim dividend, if any.

Board Composition (as of the announcement date, 17 August 2026): • Executive Director and Chairman: Dr. Gong Zhaolong • Non-Executive Directors: Ms. Zhang Wenhua, Mr. Zhou Feng, Ms. Chen Yawen • Independent Non-Executive Directors: Dr. Li Jin, Dr. Lin Tat Pang, Mr. Liu Xinguang

The notice was issued in Hong Kong on 17 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1143007118"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143007118\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143007118?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-17 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143007118","market":"us","top_or_hot":-1,"title":"3D Medicines Sets 31 Aug 2026 Board Meeting to Review H1 2026 Results and Potential Interim Dividend","media":"Bulletin Express","content":"<p>3D Medicines Inc. has scheduled a board meeting for Monday, 31 August 2026. The agenda includes:</p>\n<p>1. Approval of the unaudited interim results for the six months ended 30 June 2026.  \n2. Consideration of an interim dividend, if any.</p>\n<p>Board Composition (as of the announcement date, 17 August 2026):  \n• Executive Director and Chairman: Dr. Gong Zhaolong  \n• Non-Executive Directors: Ms. Zhang Wenhua, Mr. Zhou Feng, Ms. Chen Yawen  \n• Independent Non-Executive Directors: Dr. Li Jin, Dr. Lin Tat Pang, Mr. Liu Xinguang</p>\n<p>The notice was issued in Hong Kong on 17 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3D Medicines Sets 31 Aug 2026 Board Meeting to Review H1 2026 Results and Potential Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3D Medicines Sets 31 Aug 2026 Board Meeting to Review H1 2026 Results and Potential Interim Dividend\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-17 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>3D Medicines Inc. has scheduled a board meeting for Monday, 31 August 2026. The agenda includes:</p>\n<p>1. Approval of the unaudited interim results for the six months ended 30 June 2026.  \n2. Consideration of an interim dividend, if any.</p>\n<p>Board Composition (as of the announcement date, 17 August 2026):  \n• Executive Director and Chairman: Dr. Gong Zhaolong  \n• Non-Executive Directors: Ms. Zhang Wenhua, Mr. Zhou Feng, Ms. Chen Yawen  \n• Independent Non-Executive Directors: Dr. Li Jin, Dr. Lin Tat Pang, Mr. Liu Xinguang</p>\n<p>The notice was issued in Hong Kong on 17 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01244","symbol_name":"思路迪医药股份","start_time":0,"source_url":"","article_id":"1143007118","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143007118","pubTimestamp":1786974313,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"3D Medicines Inc. has scheduled a board meeting for Monday, 31 August 2026. The agenda includes: 1. Approval of the unaudited interim results for the six months ended 30 June 2026.   2. Consideration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01244":"思路迪医药股份"},"translate_title":"3D Medicines 定于 2026 年 8 月 31 日召开董事会会议，审查 2026 年上半年业绩和潜在中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01244":1},"content_text":"3D Medicines Inc. has scheduled a board meeting for Monday, 31 August 2026. The agenda includes:\n1. Approval of the unaudited interim results for the six months ended 30 June 2026.  \n2. Consideration of an interim dividend, if any.\nBoard Composition (as of the announcement date, 17 August 2026):  \n• Executive Director and Chairman: Dr. Gong Zhaolong  \n• Non-Executive Directors: Ms. Zhang Wenhua, Mr. Zhou Feng, Ms. Chen Yawen  \n• Independent Non-Executive Directors: Dr. Li Jin, Dr. Lin Tat Pang, Mr. Liu Xinguang\nThe notice was issued in Hong Kong on 17 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}